

InnoCyto Inc.

15375 Barranca Pkwy, Suite I-103 Irvine, CA 92618

Technical Data Sheet

PE conjugated Human PD-L2 (C-His)

Catalog Number: 813301, 813302

Size: 25 ug, 100 ug

Target Name: PDL2, , Butyrophilin B7-DC, CD273, PDCD1 ligand 2

Regulatory Status: RUO

Product Details

Application: FC
Format: Liquid, PE
Expression Host: CHO

Species: Human

Sources: Recombinant Human PD-L2 (Leu20-Pro219) with C-terminus His-tag is expressed in CHO

cell and conjugated to PE.

Accession Number: Q9BQ51

Molecular Weight: The protein has a predicted molecular weight of 24.2 kDa. Under DTT-reducing

conditions, it migrates at approximately 35 kDa on SDS-PAGE prior to conjugation.

Affinity Tag: C-His

Formulation: 1xPBS buffer, pH7.4, 0.09% NaN3 with a carrier protein

Endotoxin level: Not tested

Protein Concentration: 25μg size is bottled at 0.1mg/mL concentration. 100 μg size is bottled at lot

specific concentration.

Storage and Handling: Briefly centrifuge the vial upon receipt. An unopened vial may be stored at

2-8°C for up to six months.

Background Information

Programmed death ligand 2 (PD-L2, also known as B7-DC or CD273) is a type I transmembrane protein and a member of the B7 family, containing one V-like and one C-like Ig domain in its extracellular region. It is mainly expressed on antigen-presenting cells, such as dendritic cells, macrophages, and B cells, and its expression can be induced by IFN-? or LPS. PD-L2 serves as a high-affinity ligand for PD-1, a receptor expressed on activated T and B cells, and inhibits T cell activation, proliferation, and cytokine production, thus contributing to immune tolerance and evasion, particularly in tumors and autoimmunity. PD-L2 also plays a PD-1-independent role in asthma by regulating airway hyperresponsiveness through IL-12 production and binding to an alternative receptor, RGMb, involved in respiratory immune regulation. Its dual functions in both PD-1-dependent and independent pathways highlight PD-L2 as a critical immunoregulatory molecule and a potential therapeutic target in cancer, autoimmunity, and allergic diseases.